ITEM VIEW

Quetiapine augmentation of serotonin reuptake inhibitors in obsessive - Compulsive disorder

dc.contributor.authorMohr N.
dc.contributor.authorVythilingum B.
dc.contributor.authorEmsley R.A.
dc.contributor.authorStein D.J.
dc.date.accessioned2011-05-15T15:59:17Z
dc.date.available2011-05-15T15:59:17Z
dc.date.issued2002
dc.identifier.citationInternational Clinical Psychopharmacology
dc.identifier.citation17
dc.identifier.citation1
dc.identifier.issn2681315
dc.identifier.urihttp://hdl.handle.net/10019.1/11102
dc.description.abstractThe augmentation of serotonin reuptake inhibitors (SRIs) with atypical antipsychotics for the management of treatment-resistant obsessive-compulsive disorder (OCD) is gaining increasing acceptance. Quetiapine is a novel antipsychotic which is well tolerated, and which may therefore be particularly useful in this context. Charts of all patients treated in our OCD clinic with the combination of an SRI and quetiapine were reviewed. Demographic details and clinical symptoms on the Yale-Brown Obsessive-Compulsive Scale and the Clinical Global Impressions Scale (CGI) were tabulated before and after augmentation. Eight OCD patients who had proven resistance to treatment with SRIs had received quetiapine augmentation. Four of these eight patients were responders (CGI of 1 or 2) within 4 weeks. In the treatment-responders, the medication was well tolerated. Although limited by the retrospective design and lack of controls, these data are consistent with the growing literature suggesting that approximately one-half of OCD patients resistant to treatment with SRIs may respond to augmentation with an atypical antipsychotic. Quetiapine, a relatively well tolerated agent, deserves further controlled study in this context. © 2002 Lippincott Williams & Wilkins.
dc.subjectcitalopram
dc.subjectclomipramine
dc.subjectfluoxetine
dc.subjectfluvoxamine maleate
dc.subjectneuroleptic agent
dc.subjectquetiapine
dc.subjectrisperidone
dc.subjectserotonin uptake inhibitor
dc.subjectadult
dc.subjectarticle
dc.subjectclinical article
dc.subjectclinical feature
dc.subjectdemography
dc.subjectdrug induced disease
dc.subjectdrug potentiation
dc.subjectdrug response
dc.subjectdrug tolerability
dc.subjectfemale
dc.subjecthuman
dc.subjectmale
dc.subjectobsession
dc.subjectpriority journal
dc.subjectrating scale
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAntipsychotic Agents
dc.subjectDibenzothiazepines
dc.subjectDrug Therapy, Combination
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectObsessive-Compulsive Disorder
dc.subjectPsychiatric Status Rating Scales
dc.subjectRetrospective Studies
dc.subjectSerotonin Uptake Inhibitors
dc.titleQuetiapine augmentation of serotonin reuptake inhibitors in obsessive - Compulsive disorder
dc.typeArticle
dc.description.versionArticle


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

ITEM VIEW